Substance / Medication

Dapsone

Overview

Active Ingredient
dapsone
RxNorm CUI
3108

Indications

Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance.

Labeler: Rising Pharma Holdings, Inc.Updated: 2026-01-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Hypersensitivity to Dapsone and/or its derivatives.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of dapsone in adult immune thrombocytopenia: a systematic review and meta-analysis.
Khan Iftikhar, Qasim Soban Ali, Rath Shree et al. · Eur J Med Res · 2025
PMID: 41382219Meta-AnalysisFull text (PMC)
Utilization of dapsone and hemoglobin in the epithelial skin regeneration therapy of cutaneous loxoscelism: A case report and integrative literature review.
Azuara-Antonio Omar, Isidoro Ortiz Mario, Jiménez-Oliver Karla Daniela et al. · Sao Paulo Med J · 2024
PMID: 38422241Meta-AnalysisFull text (PMC)
Efficacy and safety of dapsone gel for acne: a systematic review and meta-analysis.
Wang Xuesong, Wang Zhenzhen, Sun Lulu et al. · Ann Palliat Med · 2022
PMID: 35249339Meta-Analysis
Risk factors for dapsone resistance in leprosy patients: a systematic meta-analysis.
Wu Ziwei, Wang Chen, Wang Zhenzhen et al. · J Glob Antimicrob Resist · 2022
PMID: 35643395Meta-Analysis
Topical dapsone in the treatment of acne: a systematic review.
Nickles Melissa A, Lake Eden · Int J Dermatol · 2022
PMID: 35132625Meta-Analysis
The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses.
Park Hye Jung, Park Jung-Won, Kim Sae Hoon et al. · Expert Opin Drug Saf · 2020
PMID: 32700588Meta-Analysis
Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis.
Tangamornsuksan Wimonchat, Lohitnavy Manupat · JAMA Dermatol · 2018
PMID: 29541744Meta-AnalysisFull text (PMC)
Features and Treatment of Dapsone-Induced Hepatitis, Based on Analysis of 44 Cases and Literature Review.
Devarbhavi Harshad, Raj Sujata, Joseph Tarun et al. · Clin Gastroenterol Hepatol · 2017
PMID: 28552804Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dapsone (substance)
SNOMED CT
387096002
UMLS CUI
C0010980
RxNorm CUI
3108
Labeler
Rising Pharma Holdings, Inc.

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.